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Abstract 34 
Purpose: The purpose of this study was to develop an alternative, more clinically relevant approach 35 
to susceptibility reporting for implant associated infections. Using 20 staphylococcal isolates, 36 
isolated from clinical implant infections, the majority (85%) demonstrated biofilm-forming 37 
capabilities. A significantly increased MBEC compared to MIC breakpoint was obtained, with 38 
MBEC values greater than 256 µg/mL for the majority of bacteria. Such a vast increase was also 39 
demonstrated for isolates defined as negligible biofilm formers via crystal violet staining, likely 40 
due to high protein content of biofilms confirmed by proteinase-K treatment.  41 
Methodology: This study employed a variety of techniques to assess minimum inhibitory 42 
concentration (MIC) and minimum biofilm eradication concentration (MBEC) of isolates tested. In 43 
addition, the nature of bacterial biofilm across a range of clinical isolates was investigated using 44 
crystal violet staining, sodium metaperiodate and proteinase-K treatment and PCR analysis. 45 
Results/Key findings: Infection of medical implants is associated with increased rates of infection 46 
and increased bacterial tolerance to antibiotic strategies. Clinical significance is due to the presence 47 
of pathogens attached to biomaterial surfaces, enclosed in an extracellular polymeric matrix termed 48 
the biofilm. This paper highlights the importance of defining the clinical susceptibility of implant 49 
associated infections in vitro using methods that are relevant to the biofilm phenotype in vivo, and 50 
highlights how current planktonic-based antimicrobial susceptibility tests are often misleading.  51 
Conclusion: The use of biofilm-relevant susceptibility tests would improve patient outcomes by 52 
enabling correct antimicrobial regimens to be rapidly identified, reducing treatment failure and 53 
halting the spread of antimicrobial resistant strains. 54 
 55 
Keywords: Antibiotic susceptibility; Antibiotic resistance; Biofilms; Biomaterials; 56 
Indwelling devices 57 
 58 
 59 
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Introduction 60 
 61 
Infection of indwelling medical devices are commonly caused by multi-drug resistant pathogens. 62 
The implant surface provides an optimum environment for microbial attachment and growth, with 63 
numerous benefits to microorganisms including increased availability of nutrients; likelihood of 64 
survival, maturation and potential for symbiotic relationships (1). This results in failure of 65 
treatment, increased spread of resistant pathogens, device removal, morbidity and increased 66 
mortality (2). A recent UK government report outlined that without significant investment in new 67 
therapies, deaths due to infection are predicted to rise to more than 10 million deaths by 2050, a 68 
figure greater than cancer (3). Pathogen susceptibility is typically determined by the minimum 69 
inhibitory concentration (MIC) as recommended either by the British Society for Antimicrobial 70 
Chemotherapy (BSAC) or the Clinical and Laboratory Standards Institute (CLSI) guidelines (4). 71 
However, successful treatment of indwelling devices usually requires eradication of the bacterial 72 
pathogens growing in a biofilm. Biofilm associated infection is extremely difficult to eradicate and 73 
as a result, treatment commonly fails. Therefore, despite their high cost to healthcare and the 74 
economy, infections of implants remain unsolved and an ongoing burden (5). 75 
The fundamental function of in vitro antimicrobial susceptibility tests (AST) in clinical 76 
laboratories is to provide the prescriber with accurate information on appropriate antimicrobial 77 
therapy (6). However, although effective against bacteria in vitro, it is well established that 78 
concentrations of antibiotics used in standard AST are not predictive of the concentrations required 79 
to eradicate infections associated with indwelling devices (7,8). In addition, studies have shown 80 
that sub-inhibitory concentration of antibiotics can both stimulate and impede biofilm formation 81 
further confusing the issue of appropriate treatment (9-11). Therefore, certain studies have 82 
suggested that a minimum biofilm eradication concentration (MBEC) would be more indicative of 83 
the antibiotic concentration required to eliminate bacteria in biofilm (12).  84 
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In addition to determining the MBEC, it would be clinically useful to characterise the 85 
degree and nature of the bacterial biofilm and the total biomass present by e.g. crystal violet (CV) 86 
staining (13) and treatment with sodium metaperiodate and proteinase-K respectively (14,15). This 87 
could, in turn, be used to inform the clinician treating the biofilm infection. For example, protease-88 
directed therapy could be used as a means of eradicating those isolates which have been shown to 89 
possess considerable protein-mediated biofilm. Furthermore, using PCR it is also possible to 90 
identify those isolates which possess the ica operon which codes for production of enzymes 91 
required for bacterial adhesion by means of polysaccharide intracellular adhesin (PIA) synthesis.  92 
This study aimed to determine the susceptibility of 20 clinical staphylococcal isolates, 93 
cultured from indwelling human devices, to a range of antibacterial agents when grown 94 
planktonically and in biofilm. In addition, we sought to determine the degree and nature of biofilm 95 
formation of the retrieved isolates and investigate the relationship between degree and mechanism 96 
of biofilm formation, possession of the ica operon and antibiotic susceptibility with a view to an 97 
alternative method of susceptibility reporting. 98 
 99 
 100 
Materials and Method 101 
 102 
Reagents 103 
CV powder, glacial acetic acid, JumpStart® Taq Polymerase, methanol, sodium metaperiodate, 104 
proteinase-K, oxacillin, tetracycline and vancomycin were obtained from Sigma-Aldrich 105 
(Gillingham, Dorset, United Kingdom). Ica primers (16) were obtained from Operon 106 
Biotechnologies (Cologne, Germany). DEPC-treated water was obtained from Ambion 107 
(Warrington, UK). Müeller Hinton Agar (MHA), Müeller Hinton Broth (MHB) and Tryptone Soya 108 
Broth (TSB) were obtained from Oxoid (Basingstoke, UK). E-tests® were obtained from Bio-Stat 109 
(Stockport, UK). Benzylpenicillin as Crystapen® was obtained from Britannia Pharmaceuticals Ltd 110 
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(Redhill, Surrey, UK). Clindamycin as clindamycin hydrochloride was obtained from Taresh Ltd 111 
(Banbridge, Northern Ireland). 112 
 113 
Bacterial Isolates  114 
Nine coagulase-negative staphylococci (CoNS) and three meticillin-sensitive Staphylococcus 115 
aureus (MSSA) clinical isolates (B1-B12) obrained from patient samples were provided by the 116 
Microbiology Department, Belfast City Hospital, Belfast Health and Social Care Trust. A further 117 
eight clinical CoNS isolates (B24-B71) were cultured following surgical removal of catheters as 118 
previously described (17). Details of site of culture are provided in Table 1. Eleven of the twenty 119 
total isolates were chosen to determine susceptibility of both CoNS and S. aureus isolates growing 120 
as biofilm, and isolates cultured from a range of indwelling clinical devices growing as biofilm 121 
(Tables 1 and 4). For all isolates tested, a negative control of sterile TSB was included.   122 
 123 
Planktonic Susceptibility Testing 124 
Antimicrobial susceptibility of all isolates was determined using the CLSI disk diffusion (DD) 125 
method and E-test® strips (18).   126 
 127 
Quantification of Biofilm Formation 128 
Bacterial biofilms were grown and classified in sterile Nunc™ 96-well microtitre plates (VWR 129 
International, Leicestershire, UK) as previously described (13), using TSB as a growth medium. 130 
Sterile TSB was also used as a negative control. Absorbance at 590nm was then measured using a 131 
Tecan Sunrise® plate reader (Tecan, Theale, Reading, United Kingdom). ODc was defined as three 132 
standard deviations above the mean optical density of the negative control (13). 133 
 134 
 135 
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Biofilm forming ability of the strains was classified as follows: 136 
OD ≤ ODc              =  non adherent (0) 137 
ODc < OD ≤ 2 x ODc             = weakly adherent (+) 138 
2 x ODc < OD ≤ 4 x ODc = moderately adherent (++) 139 
4 x ODc < OD               =  strongly adherent (+++) 140 
 141 
Antimicrobial Susceptibility of Bacterial Isolates in Biofilm 142 
Bacterial biofilms were grown in 96-well trays using TSB as previously described (13). Following 143 
overnight incubation to allow biofilm growth, the 96-well trays were washed gently with sterile 144 
PBS to remove any non-adherent bacteria. Each isolate was then exposed to five antibiotics 145 
(penicillin, oxacillin, clindamycin, tetracycline and vancomycin) ranging in doubling 146 
concentrations from 4 µg/mL – 256 µg/mL. The specific isolates chosen were to allow comparison 147 
of both CoNS and S. aureus isolates and isolates cultured from a range of indwelling clinical 148 
devices. For all isolates tested, positive and negative controls were included.   149 
 150 
Detection of the Mechanism of Biofilm Formation 151 
Bacterial biofilms were grown in 96-well trays using TSB as previously described (13).      152 
Sodium metaperiodate (NaIO4) and proteinase-K have previously been shown to degrade 153 
polysaccharide and protein-mediated biofilms respectively (19,20). Specifically, as demonstrated 154 
by Wang et al. (15), if the polysaccharideb-1, 6-N-acetyl-D-glucosamine mediates biofilm 155 
formation, treatment with metaperiodate will result in biofilm dispersal. In contrast, if biofilm 156 
formation is protein-mediated, treatment with metaperiodate will have no effect, whereas treatment 157 
with proteinase-K will result in biofilm disruption and dispersal. 158 
 159 
Following overnight incubation the plates were washed twice with 150µL sterile PBS. Plates were 160 
then simultaneously treated as follows: 161 
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Plate 1: Following discarding of the supernatant and washing, each well was filled with 200µL 162 
40mM NaIO4 solution and incubated for a further 24 hours at 4°C. After incubation, the NaIO4 163 
solution was discarded and the wells washed thoroughly with PBS. The 96-well plates were dried 164 
and stained with CV as described above. Absorbance was then measured at 590nm. 165 
Plate 2: Following discarding of supernatant and washing, each well was filled with 200µL of a 166 
proteinase-K solution (1mg/mL in 100 mM tris(hydroxymethyl)aminomethane) and incubated for 167 
4 hours at 37°C. After incubation, the proteinase-K solution was discarded and the wells washed 168 
thoroughly with PBS. The 96-well plates were dried and stained with CV as described above. 169 
Absorbance was then measured at 590nm. 170 
 171 
Detection of ica Gene 172 
A polymerase chain reaction (PCR) assay to detect the gene products of the ica operon was carried 173 
out using conditions as previously described (16) . PCR products of the expected size were 174 
visualised using gel electrophoresis and a UV-transilluminator (Gel-Doc, BioRad, Hertfordshire, 175 
UK). In addition to the test isolates, the RP62A (ATCC 35984) S. epidermidis isolate (known to 176 
form biofilms) was used as a reference biofilm-forming organism. 177 
 178 
Statistical analysis 179 
Statistical analysis was conducted where appropriate using a one-way analysis of variance 180 
(ANOVA).  In all analyses, a p value < 0.05 denoted statistical significance. Statistical analysis was 181 
performed using the SPSS® software package. 182 
 183 
 184 
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Results  185 
Planktonic Susceptibility Testing 186 
The antibacterial susceptibility of each isolate to the 10 antibiotics routinely used in the Belfast 187 
City Hospital Microbiology Department is outlined in the antibiogram (Table 2). The number of 188 
isolates sensitive to each antibiotic is also shown in Table 2. Of the 20 isolates tested, two (B1 and 189 
B24) were susceptible to all 10 antibiotics according to CLSI breakpoint guidelines. A further nine 190 
isolates showed resistance to only one antibiotic and in all of these, the antibiotic was either 191 
penicillin or erythromycin. In addition, two of the tested isolates (B37 and B5) were resistant to 192 
two and three antibiotics, respectively. Two isolates (B3 and B9) were resistant to five antibiotics 193 
while a further five isolates were resistant to six of the 10 tested antibiotics. Of the three S. aureus 194 
isolates tested, each was susceptible to all antibiotics with the exception of penicillin. As shown in 195 
Table 2, vancomycin and teicoplanin proved to be most effective with all isolates demonstrating 196 
susceptibility to both antibiotics. Conversely, penicillin was the least effective antibiotic with only 197 
six of the 20 isolates (30%) demonstrating susceptibility. In addition, erythromycin also 198 
demonstrated limited efficacy with only 8 of the 20 isolates (40%) reported as susceptible. 199 
 200 
Quantification of Biofilm Formation 201 
 202 
Results of biofilm detection are shown in Table 3. Sixteen (80%) of the isolates tested were biofilm 203 
formers. Of these 16, 8 isolates proved to be weakly (+) adherent, two isolates moderately (++) 204 
adherent and a further six strongly (+++) adherent. Of the six isolates that demonstrated strongly 205 
adherent biofilm formation all possessed the icaA, icaB and icaC operons (Table 5). 206 
 207 
Antimicrobial Susceptibility of Bacterial Isolates in Biofilm 208 
 209 
The antibacterial susceptibility of 11 of the clinical isolates growing in biofilm to five antibiotics 210 
is shown in Table 4. Of 11 isolates tested, 9 were resistant to all five antibiotics at the highest 211 
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concentration tested (256 µg/mL). Only isolate B1, with MBEC values of 32 µg/mL and 256 µg/mL 212 
for clindamycin and vancomycin respectively, and isolate B11 with an MBEC value of 32 µg/mL 213 
for vancomycin displayed any sensitivity when grown in biofilm. 214 
 215 
Mechanism of Biofilm Formation 216 
 217 
Results of the CV staining after treatment with NaIO4 and proteinase-K are shown in Fig. 1. 218 
Statistical analysis of the results using a one-way ANOVA test revealed a significant reduction (p 219 
< 0.05) in absorbance after treatment with both NaIO4 and proteinase-K, in comparison with 220 
untreated biofilm. Of the 20 isolates tested, 11 showed a decrease in absorbance in comparison with 221 
untreated biofilm, after treatment with sodium metaperiodate. In addition, 15 of the 20 isolates 222 
showed a decrease in absorbance in comparison with untreated biofilm after treatment with 223 
proteinase-K. 224 
 225 
Detection of ica Genes 226 
 227 
Following PCR, the resulting amplicons were observed using UV trans-illumination. Bands 228 
corresponding to the expected size of icaA, icaB and icaC gene products were observed at 814, 526 229 
and 989 base pairs [Fig. 2(a)-2(c)]. Upon analysis of PCR products, 9 out of 20 isolates tested 230 
displayed the icaA gene, 9 out of 20 isolates tested displayed the icaB gene and 9 out of 20 isolates 231 
tested displayed the icaC gene. Notably, the icaABC genes detected were all in the same isolates. 232 
 233 
Discussion 234 
 235 
The colonisation of indwelling medical devices by bacteria growing in biofilm is thought to be the 236 
major contributing factor in the pathogenesis of device-related infections (21). This is in part due 237 
to the high innate resistance of these organisms to antimicrobial therapy and also due to the further 238 
increased resistance to even the highest concentrations of antibiotics when growing as a biofilm, 239 
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notably when the organism possesses an ica operon (22-26). Given this relationship between 240 
bacteria in biofilm and increased resistance to antibiotic therapy, the ability of 20 isolates retrieved 241 
from indwelling devices to form biofilms was investigated, together with their resistance to 242 
conventional antimicrobial therapy.   243 
 244 
It is important to provide information on the MBEC to clinicians for several reasons. Currently lab 245 
reports only show antibiotic sensitivity to planktonic bacteria. Therefore to be accurate they could 246 
include a caveat indicating that this may not be a true reflection of the situation in the biofilm. 247 
Otherwise the lab report is not providing valid information. It could also be a means of educating 248 
the clinical team on interpreting lab results, as this should be done with due consideration of the 249 
clinical situation.  250 
 251 
As expected, the 20 isolates tested demonstrated a scope of planktonic susceptibility to the 10 252 
antibiotics tested; all isolates were susceptible to both glycopeptide antibiotics (vancomycin and 253 
teicoplanin). This is similar to previous studies which have also reported 100% susceptibility of 254 
Gram-positive isolates to vancomycin when tested planktonically (27). Of the remaining 255 
antibiotics, the variation in susceptibility can be explained by inter-species variation. Similar to the 256 
findings in this study, erythromycin resistance in staphylococcal species has previously been 257 
reported as varying from 0% in S. lugdunensis to almost 90% in S. haemolyticus (28). In addition 258 
to planktonic susceptibility as determined by the DD method, 11 of the retrieved isolates were 259 
selected to determine their antimicrobial susceptibility when grown in biofilm. As with other 260 
studies, the results reported here confirm that when in biofilm, staphylococcal isolates display 261 
resistance to antimicrobial concentrations greater than 10-1000 times greater than that of MIC 262 
breakpoints (29,30). It is of clinical significance that the isolates tested in this study were chosen to 263 
reflect typical bacterial isolates from different sites and a range of implanted devices. Therefore, 264 
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the MBEC results reported in this study demonstrate that this greatly elevated MBEC value, in 265 
comparison with established MIC breakpoints, is completely independent of any specific implant 266 
or location. Furthermore, the 11 isolates tested also displayed a variation in degree of biofilm 267 
formation from non-adherent (-) to strongly adherent (+++). As virtually all the isolates in this study 268 
displayed an MBEC of >256 µg/mL, this suggests that, although the previously described CV 269 
method (13) classifies four isolates (B2,B4, B10 and B37) as non-biofilm forming, they are able to 270 
adhere to an implant surface to some extent and subsequently form a biofilm structure. A possible 271 
explanation for this could be that charged CV stain is retained following interaction with negatively 272 
charged teichoic acids in polysaccharide-mediated biofilm but to a much lesser extent in protein-273 
mediated biofilm. Furthermore, studies have reported that protein synthesis plays a role in early 274 
biofilm formation as well as having a role in interactions with an abiotic surface (31). Therefore, 275 
those isolates which reported negligible biofilm could in fact possess a protein-based biofilm 276 
structure which displays minimal CV absorbance. A further explanation could be simply due to 277 
phenotypic variation of different bacteria in biofilm. Previous studies have reported that the amount 278 
of biofilm produced by individual S. epidermidis isolates displayed considerable phenotypical 279 
variation and that this biofilm was regulated by several factors (19,32-34). Therefore, it is possible 280 
that, depending on the degree and constitution of the biofilm, the CV could be physically or 281 
chemically prevented from giving an accurate indication of the true extent of biofilm present. In 282 
addition, the biofilm could become more saccharide (sugary) in nature in the presence of antibiotics 283 
versus a more proteinaceous one when unchallenged. 284 
 285 
Several studies have reported that sub-optimal use of certain drugs, such as tetracycline and 286 
nafcillin may lead to increased biofilm formation by means of upregulation of certain genes 287 
responsible for intracellular adhesion (11,29). As the ability to form a biofilm in microtiter plates 288 
has a strong correlation with the ability of S. epidermidis to cause disease in a clinical setting it also 289 
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is reasonable to assume that these findings would be similar to results encountered in vivo and be 290 
of clinical significance (35,36). Despite the 20 isolates showing variation in biofilm formation, as 291 
determined by CV staining, the MBEC values showed similar levels of resistance. To further 292 
investigate this, the mechanism of biofilm formation was investigated. Numerous studies have 293 
reported that staphylococcal biofilm formation occurs via a cell-surface interaction that is mediated 294 
by a number of factors such as surface proteins (37), extracellular proteins (38), PIA (39) and an 295 
autolysin encoded by the atlE gene (40). Of these factors, it is recognised that, in the majority of 296 
isolates, biofilm formation is mediated by production of PIA, synthesised by enzymes encoded by 297 
the ica operon (41). It is clear from the results of the current study that PIA does play a substantial 298 
role in biofilm formation. However, it is equally apparent that a proteinaceous mechanism also 299 
plays a fundamental role in biofilm formation of certain isolates. These findings are in agreement 300 
with previous studies for both S. epidermidis (42,43) and S. aureus (44-46). Furthermore, it has 301 
also been reported that protein factors are sufficient for biofilm formation in S. epidermidis isolates 302 
(20). In addition, studies have demonstrated that certain clinical staphylococcal isolates are biofilm 303 
positive and ica negative (47) while previous studies have reported the presence of extracellular 304 
DNA as an important factor for biofilm formation in P. aeruginosa, Streptococcus intermedius and 305 
Streptococcus mutans (48,49). In those isolates (e.g. B51 and B71) that displayed absorption (A590) 306 
after both proteinase-K and NaIO4 treatment it may be the case that, as previously reported, 307 
extracellular DNA may contribute to the biofilm formation (47). To date, numerous studies have 308 
reported the importance of PIA, synthesised by icaADBC-encoded proteins, in staphylococcal 309 
biofilm formation. Furthermore, recent studies have found a strong correlation between presence 310 
of the ica operon and strong to intermediate biofilm formation (26). It is therefore unsurprising that 311 
of the six isolates that demonstrated strongly adherent biofilm formation all possessed the icaA, 312 
icaB and icaC operons, confirming the suggestion that icaADBC is widespread in clinically 313 
significant S. epidermidis isolates (16,20,29). In addition to those isolates which were positive for 314 
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the icaA, icaB and icaC operons there are also isolates present which, although negative for these 315 
operons did produce a detectable biofilm. Although unusual, this phenotype has been previously 316 
reported, notably in a nosocomial setting (47). Under antibiotic selective pressure, normal biofilm 317 
negative/ica negative isolates are able to develop the biofilm positive/ica negative phenotype which 318 
subsequently is more resistant to vancomycin than biofilm positive/ica positive isolates. 319 
Conversely, isolates B9 and B11 are ica positive, yet only form weak biofilms. In these instances 320 
it is possible that, although the ica gene is present, for some unknown reason it is not fully 321 
expressed. 322 
 323 
The highly resistant nature of the isolates in biofilm tested in this study indicate that all clinical 324 
isolates associated with indwelling devices, even in the absence of the ica gene, are still able to 325 
form some sort of adherent structure which resists conventional antimicrobial therapy. 326 
 327 
Conclusion  328 
Although limited to 20 clinical staphylococcal isolates, the results of this study clearly indicate that 329 
although these isolates demonstrated MIC susceptibility when exposed to antibiotic therapy, they 330 
displayed a much higher MBEC when grown in biofilm. As biofilms are related to the majority of 331 
infectious diseases (50) and are recognised as playing a fundamental role in infections associated 332 
with indwelling devices, it may be necessary to employ the MBEC as a clinical breakpoint when 333 
treating certain biofilm infections as opposed to current MIC breakpoints.  334 
 335 
Although MBEC tests would incur additional laboratory costs and would be prohibitive on 336 
processing all central venous catheter (CVC) samples it could be offered on a basis of clinical need 337 
where it was imperative to keep the CVC in situ.  This may occur when a patient is seriously ill and 338 
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there is no other means of vascular access. It may also aid clinical decision making to either stop 339 
toxic antibiotics or extend the range of antibiotics tested for the MBEC. In addition, biofilm may 340 
be present while the patient is asymptotic. However, the patient may be starting chemotherapy 341 
which will compromise their immunity and if the MBEC is known it could direct the empirical 342 
antibiotic therapy when infection occurs in the agranulocytosis phase. 343 
 344 
By developing a technique to include degree of biofilm formation in conjunction with mechanism 345 
of biofilm formation, it may be possible to tailor regimens, such as protease therapy, for difficult 346 
to eradicate biofilm-mediated infections. This would serve to more closely replicate clinical 347 
infection in vitro, improving: the ability to diagnose the presence and nature of biofilm infection; 348 
the validity of antibiotic(s) prescribed; clinical outcomes and reducing the threat of antimicrobial 349 
resistance.   350 
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Table 1 Sites from which clinical isolates were cultured, including abbreviations. 
Isolate Abbreviation Location of isolation 
B1, B24, B37, B48, B49, 
B51, B63, B64, B71 
CAPD Continuous Ambulatory Peritoneal 
Dialysis Catheter or Fluid 
B2, B3, B5, B6, B8, B9 CLT Central Line Tip 
B4 PCT PermCath Tip 
B7 ELT Epidural Line Tip 
B10 JLT Jugular Line Tip 
B11 VT Venflon Tip 
B12 FLT Femoral Line Tip 
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Table 2 Antibiogram showing antibiotic susceptibility data for all isolates 
Isolate Organism Penicillin Oxacillin Erythromycin Clindamycin Fusidic 
Acid  
Tetracycline Gentamicin Vancomycin Teicoplanin Ciprofloxacin   
B1 CoNS S S S S S S S S S S 
B2 S.aureus R S S S S S S S S S 
B3 CoNS R R R R R S S S S S 
B4 S.aureus R S S S S S S S S S 
B5 CoNS R R R S S S S S S S 
B6 CoNS R R R R R S S S S R 
B7 CoNS R R R R R S S S S R 
B8 CoNS R R R R R R S S S S 
B9 CoNS R R R R S S R S S S 
B10 S.aureus R S S S S S S S S S 
B11 CoNS R R R R R S S S S R 
B12 CoNS R R R R S S R S S R 
B24 CoNS S S S S S S S S S S 
B37 CoNS R S S S R S S S S S 
B48 CoNS R S S S S S S S S S 
B49 CoNS S S R S S S S S S S 
B51 CoNS S S R S S S S S S S 
B63 CoNS R S S S S S S S S S 
B64 CoNS S S R S S S S S S S 
B71 CoNS S S R S S S S S S S 
 
 
 
Table 3 Source of isolate tested and degree of biofilm formation based on classification 
described by Stepanovic et al. (2000). ODc = 0.255 
Isolate Organism Source Biofilm Formation Absorbance (A590) 
B1 CoNS CAPD + 0.340 
B2 S. aureus CLT - 0.220 
B3 CoNS CLT ++ 0.775 
B4 S. aureus PCT - 0.211 
B5 CoNS CLT + 0.453 
B6 CoNS CLT +++ 2.762 
B7 CoNS ELT + 0.284 
B8 CoNS CLT + 0.308 
B9 CoNS CLT + 0.272 
B10 S. aureus JLT - 0.164 
B11 CoNS VT + 0.261 
B12 CoNS FLT + 0.269 
B24 CoNS CAPD +++ 1.956 
B37 CoNS CAPD - 0.230 
B48 CoNS CAPD + 0.344 
B49 CoNS CAPD +++ 2.169 
B51 CoNS CAPD +++ 2.440 
B63 CoNS CAPD ++ 0.659 
B64 CoNS CAPD +++ 1.242 
B71 CoNS CAPD +++ 3.720 
 
 
 
 
 
 
 
 
 
 
Table 4 MBEC (µg/mL) of bacterial isolates in biofilm 
Isolate Antibiotic 
Penicillin Oxacillin Clindamycin Tetracycline Vancomycin 
B1 >256 >256 32 >256 256 
B2 >256 >256 >256 >256 >256 
B4 >256 >256 >256 >256 >256 
B6 >256 >256 >256 >256 >256 
B10 >256 >256 >256 >256 >256 
B11 >256 >256 >256 >256 32 
B24 >256 >256 >256 >256 >256 
B37 >256 >256 >256 >256 >256 
B48 >256 >256 >256 >256 >256 
B51 >256 >256 >256 >256 >256 
B71 >256 >256 >256 >256 >256 
 
Table 5 Key of isolates in Figures 4a-4c 
Number 1 2 3 4 5 6 7 8 9 10 11 
Isolate B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 
Ica 
operon 
           
Number 12 13 14 15 16 17 18 19 20 21 22 
Isolate B12 B24 B37 B48 B49 B51 B63 B64 B71 +ve -ve 
Ica 
operon 
           
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